News

Proteomics reports positive results for PromarkerEso oesophageal cancer test – Medical Device Network

Proteomics International has reported positive results from the clinical validation study of its PromarkerEso diagnostic blood test, designed to detect oesophageal adenocarcinoma.

This test is intended for the early detection and treatment of the illness, a predominant form of oesophagal cancer.

Proteomics’ PromarkerEso blood test is designed to evaluate the levels of four glycoproteins along with a patient’s age and BMI to generate a risk score. High-risk patients are advised to undergo an endoscopy.

Article

Subscribe

  • This field is for validation purposes and should be left unchanged.